LON:HVO hVIVO (HVO) Share Price, News & Analysis GBX 7 -0.30 (-4.11%) As of 12:08 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About hVIVO Stock (LON:HVO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get hVIVO alerts:Sign Up Key Stats Today's Range 6.80▼ 7.2050-Day Range 7.30▼ 10.9052-Week Range 6.50▼ 30Volume4.70 million shsAverage Volume2.92 million shsMarket Capitalization£48.11 millionP/E Ratio909.09Dividend Yield0.03%Price TargetGBX 23Consensus RatingBuy Company Overview hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. Read More hVIVO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreHVO MarketRank™: hVIVO scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatinghVIVO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialhVIVO has a consensus price target of GBX 23, representing about 228.6% upside from its current price of GBX 7.Amount of Analyst CoveragehVIVO has only been the subject of 2 research reports in the past 90 days.Read more about hVIVO's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of hVIVO is 909.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 234.45.Price to Earnings Ratio vs. SectorThe P/E ratio of hVIVO is 909.09, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 85.66.Price to Book Value per Share RatiohVIVO has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HVO. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldhVIVO pays a meaningful dividend of 2.56%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthhVIVO does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of hVIVO is 25.97%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about hVIVO's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for HVO. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added hVIVO to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, hVIVO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.43% of the stock of hVIVO is held by insiders.Percentage Held by InstitutionsOnly 4.57% of the stock of hVIVO is held by institutions.Read more about hVIVO's insider trading history. Receive HVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for hVIVO and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HVO Stock News HeadlineshVIVO (LON:HVO) Stock Price Down 3.3% After Analyst DowngradeSeptember 26, 2025 | americanbankingnews.comShore Capital Has Lowered Expectations for hVIVO (LON:HVO) Stock PriceSeptember 25, 2025 | americanbankingnews.comClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...October 6 at 2:00 AM | Angel Publishing (Ad)hVIVO Reports Interim Results and Eyes Growth in 2026September 23, 2025 | msn.com2 undervalued penny stocks to consider this SeptemberSeptember 11, 2025 | msn.comhVIVO to Release Interim Results and Host Investor PresentationSeptember 4, 2025 | tipranks.comhVIVO Appoints Shaun Chilton as Non-Executive Chair to Drive GrowthSeptember 1, 2025 | tipranks.comDon’t get caught short! Here’s how to identify penny stocks with long-term potentialJune 28, 2025 | msn.comSee More Headlines HVO Stock Analysis - Frequently Asked Questions How have HVO shares performed this year? hVIVO's stock was trading at GBX 20.50 on January 1st, 2025. Since then, HVO stock has decreased by 65.9% and is now trading at GBX 7. How were hVIVO's earnings last quarter? hVIVO plc (LON:HVO) released its earnings results on Tuesday, September, 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter. hVIVO had a trailing twelve-month return on equity of 47.93% and a net margin of 25.96%. How do I buy shares of hVIVO? Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of hVIVO own? Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), IQE (IQE) and Rolls-Royce Holdings plc (RR). Company Calendar Last Earnings9/23/2025Today10/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HVO Previous SymbolLON:RVG CIKN/A Webhvivo.com Phone+44-20-77561300FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for hVIVOGBX 23 High Price TargetGBX 25 Low Price TargetGBX 21 Potential Upside/Downside+228.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.01 Trailing P/E Ratio909.09 Forward P/E Ratio4.52 P/E GrowthN/ANet Income£17.84 million Net Margins25.96% Pretax MarginN/A Return on Equity47.93% Return on Assets11.97% Debt Debt-to-Equity Ratio33.86 Current Ratio1.61 Quick Ratio1.16 Sales & Book Value Annual Sales£51.28 million Price / Sales0.94 Cash FlowGBX 1.42 per share Price / Cash Flow4.94 Book ValueGBX 5.56 per share Price / Book1.26Miscellaneous Outstanding Shares687,216,000Free FloatN/AMarket Cap£48.11 million OptionableNot Optionable Beta0.97 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (LON:HVO) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.